Document Detail

Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
MedLine Citation:
PMID:  9869154     Owner:  NLM     Status:  MEDLINE    
RATIONALE: Reocclusion after thrombolysis diminishes the benefits of early reperfusion after acute myocardial infarction (AMI). No clinical or laboratory variables have been identified as predictors for reocclusion yet. METHODS AND RESULTS: To evaluate hemostatic variables as potential risk determinants platelet aggregation (PA, representing platelet activity), thrombin/antithrombin complexes (TAT, representing thrombin generation), and plasminogen activator inhibitor type 1 (PAI-1, representing endogenous fibrinolysis) were determined in 31 patients with AMI at 0, 1, 2. and 12 h after the start of thrombolysis as well as at hospital discharge. Reocclusion (defined as reinfarction or angiographically confirmed, clinically silent coronary reocclusion) occurred in 5 patients within 5-14 days and in 8 patients within 1 year. TAT plasma concentrations were lower in patients with reocclusion than in those without (9.9+/-5.7 vs. 22.9+/-22.2 ng/ml at 2 h, 6.5+/-3.1 vs. 1 1.2+/-6.4 ng/ml at 12 h, means+/-SD, p <0.05 each). Neither concentration nor activity of PAI-1 in plasma differed between both patient groups. However, both slope and maximum of PA (induced by 2 micromol/l ADP) were augmented in patients with reocclusion (slope: 39.4+/-1.7 vs. 32.5+/-7.4 at 2 h, p <0.001; 42.6+/-2.6 vs. 36.6+/-8.9 at 12 h, p <0.01). Results were independent of the thrombolytic agent used (alteplase or reteplase). A PA slope at 2 h higher than the average slope before thrombolysis (37.2+/-5.7) could be identified as best predictor for early (within 5-14 d, p=0.017, sensitivity 1.00, specificity 0.69) and late reocclusion (within 1 y, p=0.009, 0.88 and 0.74, respectively). CONCLUSIONS: Increased PA following coronary thrombolysis appears to be associated with early and late reocclusion. This marker could be useful in identifying patients who may benefit from more aggressive antiplatelet (such as GP IIb/IIIa receptor antagonists), interventional, or both strategies.
T K Nordt; M Moser; B Kohler; J Ruef; K Peter; W Kübler; C Bode
Related Documents :
4851404 - Disseminated intravascular coagulation as a complication of abdominal aortic aneurysm r...
8880244 - Cleavage of plasma high molecular weight kininogen in surgical icu patients.
17875234 - Prothrombotic coagulation abnormalities in patients with paraprotein-producing b-cell d...
3033024 - Gene deletions correlate with the development of alloantibodies in von willebrand disease.
9108814 - Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and r...
3833894 - Comparison of a new ultrafiltration method for serum free t4 and free t3 with two ria k...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  80     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  1998 Dec 
Date Detail:
Created Date:  1999-04-15     Completed Date:  1999-04-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  881-6     Citation Subset:  IM    
Abteilung Kardiologie, Medizinische Klinik und Poliklinik, Ruprecht-Karls-Universität Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenosine Diphosphate / pharmacology
Aged, 80 and over
Anticoagulants / administration & dosage,  therapeutic use
Antithrombin III / analysis
Aspirin / administration & dosage,  therapeutic use
Coronary Vessels / pathology
Diabetes Mellitus / epidemiology
Drug Therapy, Combination
Heparin / administration & dosage,  therapeutic use
Middle Aged
Myocardial Infarction / blood*,  drug therapy,  epidemiology
Obesity / epidemiology
Peptide Fragments
Peptide Hydrolases / analysis
Plasminogen Activator Inhibitor 1 / analysis
Plasminogen Activators / therapeutic use*
Platelet Aggregation* / drug effects
Predictive Value of Tests
Recombinant Proteins / therapeutic use
Risk Factors
Smoking / epidemiology
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use*
Vascular Patency
Reg. No./Substance:
0/Anticoagulants; 0/Peptide Fragments; 0/Plasminogen Activator Inhibitor 1; 0/Recombinant Proteins; 0/antithrombin III-protease complex; 0/prothrombin fragment 1.2; 133652-38-7/reteplase; 50-78-2/Aspirin; 58-64-0/Adenosine Diphosphate; 9000-94-6/Antithrombin III; 9001-26-7/Prothrombin; 9005-49-6/Heparin; EC 3.4.-/Peptide Hydrolases; EC 3.4.21.-/Plasminogen Activators; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease...
Next Document:  A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarctio...